AI assistant
BIO-RAD LABORATORIES, INC. — Director's Dealing 2024
Feb 29, 2024
30786_dirs_2024-02-28_59530c16-ceee-419d-821e-240cd6222b1f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-RAD LABORATORIES, INC. (BIO BIOB)
CIK: 0000012208
Period of Report: 2024-02-27
Reporting Person: Crowley Michael (EVP, GBL Commercial Operations)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-27 | Bio-Rad A Common Stock | M | 3000 | $215.98 | Acquired | 9942.0000 | Direct |
| 2024-02-27 | Bio-Rad A Common Stock | S | 3000 | $336.00 | Disposed | 6942.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | Non-Qualified Stock Option (right to buy) | $215.98 | M | 3000 | Disposed | 2027-09-05 | Bio-Rad A Common Stock (3000) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $335.53 to $336.20, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option, representing a right to purchase a total of 3,000 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted.